Cartesian Therapeutics (RNAC) Current Leases (2019 - 2026)

Cartesian Therapeutics (RNAC) has 8 years of Current Leases data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, Current Leases rose 13.01% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 13.01% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 45.6% from the prior year.
• Current Leases for Q1 2026 stood at $4.2 million, up from $4.2 million in the prior quarter.
• Over the last five years, Current Leases for RNAC reached as high as $4.2 million in Q1 2026 and fell as low as $1.1 million in Q1 2022.
• Historically, Current Leases has averaged $2.5 million across 5 years, with a median of $2.2 million in 2024.
• Across the five-year window, Current Leases surged 66.17% in 2025 and increased 13.01% in 2026, its largest moves.
• Year by year, Current Leases stood at $1.6 million in 2022, then jumped by 34.7% to $2.2 million in 2023, then soared by 31.63% to $2.9 million in 2024, then jumped by 45.6% to $4.2 million in 2025, then gained by 0.84% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $4.2 million in Q1 2026, $4.2 million in Q4 2025, and $3.9 million in Q3 2025.